Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
